CN100582230C - 通过载体构建体与细胞dna的非同源重组来表达内源基因 - Google Patents

通过载体构建体与细胞dna的非同源重组来表达内源基因 Download PDF

Info

Publication number
CN100582230C
CN100582230C CN98811571A CN98811571A CN100582230C CN 100582230 C CN100582230 C CN 100582230C CN 98811571 A CN98811571 A CN 98811571A CN 98811571 A CN98811571 A CN 98811571A CN 100582230 C CN100582230 C CN 100582230C
Authority
CN
China
Prior art keywords
cell
gene
sequence
construct
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN98811571A
Other languages
English (en)
Chinese (zh)
Other versions
CN1280615A (zh
Inventor
约翰·J·哈林顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Athersys Inc
Original Assignee
Athersys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athersys Inc filed Critical Athersys Inc
Publication of CN1280615A publication Critical patent/CN1280615A/zh
Application granted granted Critical
Publication of CN100582230C publication Critical patent/CN100582230C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN98811571A 1997-09-26 1998-09-25 通过载体构建体与细胞dna的非同源重组来表达内源基因 Expired - Lifetime CN100582230C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94122397A 1997-09-26 1997-09-26
US08/941,223 1997-09-26
US15964398A 1998-09-24 1998-09-24
US09/159,643 1998-09-24

Publications (2)

Publication Number Publication Date
CN1280615A CN1280615A (zh) 2001-01-17
CN100582230C true CN100582230C (zh) 2010-01-20

Family

ID=26856150

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98811571A Expired - Lifetime CN100582230C (zh) 1997-09-26 1998-09-25 通过载体构建体与细胞dna的非同源重组来表达内源基因

Country Status (14)

Country Link
EP (1) EP1017803B1 (https=)
JP (1) JP5377806B2 (https=)
KR (1) KR20010024296A (https=)
CN (1) CN100582230C (https=)
AT (1) ATE471373T1 (https=)
AU (1) AU750025B2 (https=)
BR (1) BR9812540A (https=)
CA (1) CA2304642C (https=)
DE (1) DE69841723D1 (https=)
DK (1) DK1017803T3 (https=)
IL (2) IL135242A0 (https=)
NO (1) NO20001497L (https=)
NZ (1) NZ504185A (https=)
WO (1) WO1999015650A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740503B1 (en) 1997-09-26 2004-05-25 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
WO2000049162A2 (en) * 1999-02-19 2000-08-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
JP2003527833A (ja) 1999-10-14 2003-09-24 クロンテック・ラボラトリーズ・インコーポレーテッド 花虫類に由来する発色団／蛍光体、およびそれらの使用法
ES2391124T3 (es) 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
GB0018876D0 (en) 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
AU2002227069A1 (en) * 2000-10-30 2002-05-15 Novozymes Biotech, Inc. Methods for expressing endogenous genes by restriction enzyme mediated integration
AU2002343616A1 (en) 2001-11-02 2003-05-19 Athersys, Inc. Methods for mutating genes in cells and animals using insertional mutagenesis
WO2003054158A2 (en) 2001-12-19 2003-07-03 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
US7662924B2 (en) 2002-02-22 2010-02-16 The Board Of Trustees Of The University Of Illinois Beta chain-associated regulator of apoptosis
DK1534819T3 (da) 2002-08-21 2010-04-19 Revivicor Inc Griselignende dyr, som mangler enhver ekspression af funktionel alfa-1,3-galactosyltransferase
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US8021833B2 (en) 2003-02-12 2011-09-20 Functional Genetics, Inc. Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
AU2005223617A1 (en) 2004-03-17 2005-09-29 Revivicor, Inc. Tissue products from animals lacking functional alpha 1,3 galactosyl transferase
EP1732944B1 (en) 2004-04-07 2012-09-05 The University of Chicago Monomeric red fluorescent proteins
BRPI0513826A2 (pt) 2004-07-26 2010-06-22 Dow Global Technologies Inc processo para expressão de proteìna melhorada através de engenharia de cepa
CA2958259C (en) 2004-10-22 2020-06-30 Revivicor, Inc. Ungulates with genetically modified immune systems
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EP1891107B1 (en) 2005-05-12 2011-07-06 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
EP3138403A1 (en) 2005-08-09 2017-03-08 Revivicor, Inc. Transgenic ungulates expressing ctla4-ig and uses thereof
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
CN101511868B (zh) 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2009059305A2 (en) 2007-11-01 2009-05-07 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
WO2009073511A2 (en) 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphisms of the blys gene and use in diagnostic methods
EP2525808A2 (en) 2010-01-19 2012-11-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
CN102669057B (zh) * 2011-03-18 2014-11-26 上海南方模式生物科技发展有限公司 一种调控动物内源基因表达的遗传修饰方法
KR101948248B1 (ko) * 2011-11-18 2019-02-14 한국생명공학연구원 단백질 발현 미세 조절방법
US9957515B2 (en) 2013-03-15 2018-05-01 Cibus Us Llc Methods and compositions for targeted gene modification
WO2014152497A2 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
KR102450868B1 (ko) * 2014-03-14 2022-10-06 시버스 유에스 엘엘씨 올리고뉴클레오타이드 매개 유전자 보수를 사용한 표적화된 유전자 변형의 효율을 증가시키기 위한 방법 및 조성물
JP7175608B2 (ja) 2014-11-19 2022-11-21 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 加齢に伴うフレイルのための治療としてのオステオカルシン
CA3100376A1 (en) 2018-05-15 2019-11-21 Duke University Systems and methods for genetic manipulation of akkermansia species

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204939A (en) * 1989-12-14 1993-04-20 Fujitsu Limited Rule base processing system and rule evaluation control method therein
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
WO1995031560A1 (en) * 1994-05-13 1995-11-23 Transkaryotic Therapies, Inc. Dna construct for effecting homologous recombination and uses thereof
WO1996029411A1 (en) * 1995-03-17 1996-09-26 Transkaryotic Therapies, Inc. Protein production and delivery
US5578461A (en) * 1989-11-06 1996-11-26 Cell Genesys, Inc. Gene manipulation and expression using genomic elements

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5561053A (en) * 1994-08-05 1996-10-01 Genentech, Inc. Method for selecting high-expressing host cells
WO2000049162A2 (en) * 1999-02-19 2000-08-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578461A (en) * 1989-11-06 1996-11-26 Cell Genesys, Inc. Gene manipulation and expression using genomic elements
US5204939A (en) * 1989-12-14 1993-04-20 Fujitsu Limited Rule base processing system and rule evaluation control method therein
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
WO1995031560A1 (en) * 1994-05-13 1995-11-23 Transkaryotic Therapies, Inc. Dna construct for effecting homologous recombination and uses thereof
WO1996029411A1 (en) * 1995-03-17 1996-09-26 Transkaryotic Therapies, Inc. Protein production and delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A new strategy of gene trapping in ES cells using 3'RACE.Michio Yoshida et al.Transgenic Research,Vol.4. 1995 *

Also Published As

Publication number Publication date
JP2003535564A (ja) 2003-12-02
EP1017803B1 (en) 2010-06-16
EP1017803A1 (en) 2000-07-12
CA2304642C (en) 2014-11-18
AU750025B2 (en) 2002-07-11
IL135242A0 (en) 2001-05-20
NO20001497D0 (no) 2000-03-22
BR9812540A (pt) 2001-12-26
DK1017803T3 (da) 2010-08-23
ATE471373T1 (de) 2010-07-15
KR20010024296A (ko) 2001-03-26
CA2304642A1 (en) 1999-04-01
WO1999015650A1 (en) 1999-04-01
IL135242A (en) 2011-06-30
HK1027375A1 (en) 2001-01-12
AU9581698A (en) 1999-04-12
DE69841723D1 (de) 2010-07-29
WO1999015650A9 (en) 2000-09-08
NO20001497L (no) 2000-05-25
JP5377806B2 (ja) 2013-12-25
NZ504185A (en) 2003-02-28
CN1280615A (zh) 2001-01-17
EP1017803A4 (en) 2002-01-09

Similar Documents

Publication Publication Date Title
CN100582230C (zh) 通过载体构建体与细胞dna的非同源重组来表达内源基因
US6897066B1 (en) Compositions and methods for non-targeted activation of endogenous genes
US5968502A (en) Protein production and protein delivery
ES2263206T3 (es) Adn regulador transcripcional de ef-1-alfa de hamster.
UA34493C2 (uk) Спосіб одержання гомологічно рекомбінантної клітини (варіанти), плазміда для використання у способі (варіанти), штам гомологічно рекомбінантних клітин фібросаркоми людини (варіанти), спосіб одержання еритропоетину людини (варіанти)
CN109136272A (zh) 用于特异性修复人hbb基因突变的碱基编辑系统、方法、试剂盒及其在人生殖系中的应用
JPH09510865A (ja) マウス細胞のための相同的組換え抗体発現系
EP1155131B1 (en) Vector comprising a splice acceptor trap and a poly a trap and the corresponding eukaryotic host cells
CN110885799A (zh) 一种基于腺病毒的基因编辑方法
CN108012545B (zh) 包含珠蛋白基因簇的调控元件的真核表达载体
JPH05503015A (ja) 哺乳類発現ベクター
JP2005504552A (ja) ターゲティングベクターの調製方法およびその使用
CN107034234A (zh) 一种用于敲除cho细胞中fut8和dhfr两种基因的试剂盒
EA020311B1 (ru) Вектор на основе искусственной хромосомы
TWI245048B (en) Methods and constructs for protein expression
EA011619B1 (ru) Экспрессионный вектор и способ продуцирования высоких уровней белков
US7316923B1 (en) Compositions and methods for non-targeted activation of endogenous genes
CN101341252A (zh) 啮齿动物细胞中的蛋白质表达
US20110217779A1 (en) Compositions and Methods for Non-Targeted Activation of Endogenous Genes
HK1027375B (en) Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna
CN114807155A (zh) 用于基因编辑的组合物及其应用
MXPA01008415A (en) Compositions and methods for non-targeted activation of endogenous genes
Liu Human hematopoietic stem cell gene therapy
ZA200106777B (en) Compositions and methods for non-targeted activation of endogeneous genes.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20100120

CX01 Expiry of patent term